Table 1 Demographics and characteristics of study patients by baseline CD4 strata and HIV type
From: Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire
Baseline CD4 < 200 cells/μl | Baseline CD4 200–500 cells/μl | ||||||||
|---|---|---|---|---|---|---|---|---|---|
HIV-1 | HIV-2 | HIV-D | Total | HIV-1 | HIV-2 | HIV-D | Total | ||
Total patients, n | 2165 | 77 | 108 | 2350 | 1049 | 31 | 57 | 1137 | 3487 |
Visits, median (IQR) | 7.0 (3–19) | 7.0 (3–16) | 7.0 (3–17) | 7.0 (3–19) | 8.0 (3–18) | 11.0 (3–21) | 7.5 (3–18.5) | 8.0 (3–18) | 7.0 (3–19) |
Follow-up time (years), median (IQR) | 3.8 (0.7–11.2) | 3.0 (0.8–8.0) | 2.5 (0.7–10.7) | 3.7 (0.7–11.2) | 4.5 (1.0–11.3) | 5.6 (2.6–10.6) | 4.7 (1.4–11.0) | 4.6 (1.0–11.3) | 4.0 (0.8–11.2) |
Year of baseline CD4, n (%) | |||||||||
1998–2000 | 444 (20.5) | 15 (19.5) | 29 (26.9) | 488 (20.8) | 254 (24.2) | 8 (25.8) | 11 (19.3) | 273 (24.0) | 761 (21.8) |
2001–2002 | 768 (35.5) | 31 (40.3) | 40 (37.0) | 839 (35.7) | 394 (37.6) | 10 (32.3) | 27 (47.4) | 431 (37.9) | 1270 (36.4) |
2003–2004 | 953 (44.0) | 31 (40.3) | 39 (36.1) | 1023 (43.5) | 401 (38.2) | 13 (41.9) | 19 (33.3) | 433 (38.1) | 1456 (41.8) |
CD4 count (cells/μl), median (IQR) | 69 (21–127) | 69 (42–112) | 71 (23–125) | 69 (22–126) | 299 (246–381) | 282 (236–373) | 312 (250–382) | 299 (246–381) | 128 (41–244) |
Age (years) | |||||||||
Age, mean ± SD | 37.8 ± 8.7 | 43.8 ± 8.3 | 41.4 ± 6.6 | 38.2 ± 8.7 | 36.7 ± 9.4 | 41.3 ± 9.3 | 39.7 ± 8.3 | 37.0 ± 9.4 | 37.8 ± 9.0 |
< 35, n (%) | 837 (38.7) | 8 (10.4) | 15 (13.9) | 860 (36.6) | 487 (46.4) | 6 (19.4) | 17 (29.8) | 510 (44.9) | 1370 (39.3) |
35–44, n (%) | 844 (39.0) | 39 (50.6) | 57 (52.8) | 940 (40.0) | 358 (34.1) | 11 (35.5) | 28 (49.1) | 397 (34.9) | 1337 (38.3) |
≥ 45, n (%) | 484 (22.4) | 30 (39.0) | 36 (33.3) | 550 (23.4) | 204 (19.4) | 14 (45.2) | 12 (21.1) | 230 (20.2) | 780 (22.4) |
Sex, n (%) | |||||||||
Female | 1107 (51.1) | 33 (42.9) | 37 (34.3) | 1177 (50.1) | 626 (59.7) | 11 (35.5) | 29 (50.9) | 666 (58.6) | 1843 (52.9) |
Male | 1058 (48.9) | 44 (57.1) | 71 (65.7) | 1173 (49.9) | 423 (40.3) | 20 (64.5) | 28 (49.1) | 471 (41.4) | 1644 (47.2) |
Percentage of visits with documented ART regimen, n (%) | |||||||||
< 50% | 216 (10.0) | 8 (10.4) | 12 (11.1) | 236 (10.0) | 307 (29.2) | 8 (25.8) | 15 (26.3) | 330 (29.0) | 566 (16.2) |
50–75% | 614 (28.3) | 26 (33.7) | 31 (28.7) | 671 (28.6) | 229 (21.8) | 6 (19.4) | 17 (29.8) | 252 (22.2) | 923 (26.5) |
> 75% | 1335 (61.7) | 43 (55.8) | 65 (60.1) | 1443 (61.4) | 513 (48.9) | 17 (54.8) | 25 (43.8) | 555 (48.8) | 1998 (57.3) |